How adolescents with inflammatory bowel disease treated with immunosuppressive drugs respond to COVID-19 vaccination

In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive drugs or given as monotherapy, after a first dose of Pfizer-BioNTech’s Comirnaty vaccine.

2022-04-22T15:41:26-04:00November 30, 2021|Pediatrics|

Preliminary results suggest nearly 6% of Montreal children tested from October to April had antibodies to SARS-CoV-2

Preliminary results from a study underway in Montreal shed important light on the extent to which 2 to 17 years-old have had COVID-19 between last October 2020 and this April 2021. As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.

2021-05-17T21:43:27-04:00May 18, 2021|Media Releases, Pediatrics|
Go to Top